Table 4 Overall prevalence of COVID-19 like symptoms in participants without and with neutralising antibodies in participants with neutralising antibodies evaluated in sera from the initial blood draw (day 0).

From: Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults

 

NT neg/not done

NT pos

  

Symptoms

n (%)

n (%)

Prevalence

p-value

Cough

341 (20.8%)

4 (30.8%)

1.2%

0.489

Fever/elevated body temp.

214 (13.0%)

7 (53.8%)

3.2%

0.001

Sore throat

205 (12.5%)

6 (46.2%)

2.8%

0.003

Rhinitis

212 (12.9%)

4 (30.8%)

1.9%

0.078

Body aches

55 (3.3%)

1 (7.7%)

1.8%

0.362

Faintness

68 (4.1%)

3 (23.1%)

4.2%

0.016

Headache

55 (3.3%)

2 (15.4%)

3.5%

0.071

Common cold

87 (5.3%)

1 (7.7%)

1.1%

0.510

Shivers

19 (1.2%)

1 (7.7%)

5.0%

0.147

Dyspnea

27 (1.6%)

2 (15.4%)

6.9%

0.021

Thoracical pain

14 (0.9%)

1 (7.7%)

6.7%

0.112

Gastrointestinal symptoms

24 (1.5%)

2 (15.4%)

7.7%

0.017

Anosmia/dysgeusia

6 (0.4%)

9 (69.2%)

60.0%

<0.001

Other

23 (1.4%)

1 (7.7%)

4.2%

0.174

Any symptom

669 (40.7%)

13 (100.0%)

1.9%

<0.001

  1. Neutralising test (NT).
  2. Bold values refer to significant results (p-value < 0.05)
Back to article page